Moreover, KS18 reduced Mcl-1 expression in MM-resistant cells Figure 5B, this indicates the KS18’s potential as a viable therapeutic alternative for surmounting resistance in MM cells (Figure 5B). This evidence concerns the gene MCL1 and Miyoshi myopathy.